Moncler has always believed in research and innovation as key drivers for continuous development and improvement. This belief goes beyond Company boundaries, Moncler is committed to promoting research in the medical and scientific sector,

which it actively supports through funding and grants.
In 2019, a total of 600 thousand euros was earmarked for research grants and loans to support researchers at the Umberto Veronesi Foundation,

and for donations to a number of associations and foundations involved in medical research and in supporting the ill, including Theodora.


The Umberto Veronesi Foundation was established in 2003 to support scientific research of excellence. Its promoters include 11 Nobel Prize winners, who form the Foundation’s Honorary Committee.

The Foundation supports medical and scientific research through grants for physicians and researchers involved in the most advanced fields of oncology, cardiology, and neuroscience. Since its inception, the Foundation has funded nearly 1,600 researchers involved in cutting-edge scientific projects.

Furthermore, it actively disseminates scientific information through conferences, projects with schools, awareness campaigns and publications.

In 2013, the Foundation launched the Pink is Good project to support breast cancer research and raise prevention awareness across the community. Moncler has actively supported this project since its inception, by donating part of the revenues generated by its main Italian retail stores during one day in October every year, and by handing out information brochures to clients to raise prevention awareness. In 2019, once again, Moncler supported four of the Umberto Veronesi Foundation’s researchers, working on research into breast and pancreas cancer. Moncler also continued to support the Foundation’s commitment to pediatric oncology by contributing to the Gold for Kids project, which aims to raise awareness

of the delicate issue of pediatric and adolescent cancer. It promotes research and contributes to the development of innovative treatment protocols capable of delivering cutting-edge therapies and higher chances of recovery. In 2019, in order to promote research into treatment as well as diagnosis, Moncler continued to fund a three-year study to assess the risk of secondary leukaemia in cancer survivors. The study will analyse the DNA of children who survived cancer, in order to develop a genetic test to predict risk and enable the early diagnosis of blood diseases resulting from cancer therapies.